Ranbaxy Labs is set to launch olmesartan medoxomil, an anti-hypertensive, under the brand name Olvance in six African countries viz., Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia. The product is originally discovered by Daiichi. This is the first time in Africa that Daiichi and Ranbaxy are leveraging mutual synergies. Olmesartan medoxomil is a member of the Angiotensin receptor blocker (ARB) class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the release of hormone which causes salt retention and increased blood volume. Olmesartan medoxomil is available in more than 50 countries worldwide. Ranbaxy launched olmesartan medoxomil as Olvance in India in April 2009, followed by the August launch of Ol-Vamlo, a fixed-dose combination of olmesartan medoxomil with amlodipine besylate.
No comments:
Post a Comment